Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SanBio Co ( (JP:4592) ) has provided an announcement.
SanBio Co., Ltd. announced that its application for a partial change in marketing approval for AKUUGO Suspension for Intracranial Implantation will be reviewed by regulatory authorities, with a decision expected by January 2026. The outcome of this review is anticipated to have minimal financial impact for the current fiscal year, but it could enhance SanBio’s position in the regenerative medicine market by potentially expanding the use of its stem cell-based product for brain injury treatment.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001 and headquartered in Tokyo, Japan, is a leader in regenerative medicine. The company focuses on the research, development, manufacture, and sale of regenerative cell medicines, particularly targeting central nervous system disorders with unmet medical needs.
Average Trading Volume: 2,274,127
Technical Sentiment Signal: Buy
Current Market Cap: Yen175.1B
See more data about 4592 stock on TipRanks’ Stock Analysis page.